FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1918584766> ?p ?o ?g. }

• W1918584766 abstract "The combination of sofosbuvir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of SOF and RBV for the treatment of patients infected with hepatitis c virus (HCV) has improved rates of sustained virological response (SVR) considerably in recent trials. However, there is only limited data concerning the efficacy and safety in a “real-life” cohort. We analyzed a cohort of 119 patients with chronic HCV infection treated at four investigational sites in Germany. All patients received either a combination treatment of SOF, RBV and peg-IFN-alfa-2a or SOF and RBV. The rates of SVR at 12 weeks after end of treatment (SVR 12) were as follows: Among 76 patients with genotype 1 infection the SVR 12 rate was 74 % (n = 56), among 14 patients with genotype 2 infection the SVR 12 rate was 79 % (n = 11), among 24 patients with genotype 3 infection the SVR 12 rate was 92 % (n = 22) and among 5 patients with genotype 4 infection the SVR 12 rate was 80 % (n = 4). Of all 26 patients with a relapse in our cohort, 69 % (n = 18) of these patients presented with liver cirrhosis and 58 % (n = 15) were treatment experienced. Notably, the level of HCV-RNA after 4 weeks of treatment was a significant predictor of treatment response in genotype 1 patients. Patients with HCV-RNA levels ≥ 12 IU ml-1 after 4 weeks of treatment achieved SVR 12 only in 30 % (n = 17/56, p < 0.0001) of cases and treatment response was even lower with SVR 12 of 25 % (n = 5/20, p = 0.0016) in the subgroup of patients with cirrhosis. We observed a high rate of SVR 12 with SOF-based treatment regimes, however probably due to the high number of patients with liver cirrhosis and prior treatment experience, treatment response rates were lower than in previously published trials. In genotype 1 patients the analysis of early virological response may predict treatment response in SOF-based combination therapies." @default.
• W1918584766 created "2016-06-24" @default.
• W1918584766 creator A5009529288 @default.
• W1918584766 creator A5015644990 @default.
• W1918584766 creator A5024301901 @default.
• W1918584766 creator A5025956524 @default.
• W1918584766 creator A5035616011 @default.
• W1918584766 creator A5043687105 @default.
• W1918584766 creator A5044320481 @default.
• W1918584766 creator A5056815916 @default.
• W1918584766 creator A5058992298 @default.
• W1918584766 creator A5063340992 @default.
• W1918584766 creator A5072719414 @default.
• W1918584766 creator A5090959657 @default.
• W1918584766 date "2015-08-04" @default.
• W1918584766 modified "2023-10-18" @default.
• W1918584766 title "Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center “real-life” cohort" @default.
• W1918584766 cites W1502617719 @default.
• W1918584766 cites W1970160203 @default.
• W1918584766 cites W1987935503 @default.
• W1918584766 cites W1992973138 @default.
• W1918584766 cites W2003104968 @default.
• W1918584766 cites W2004360699 @default.
• W1918584766 cites W2006881280 @default.
• W1918584766 cites W2022687771 @default.
• W1918584766 cites W2040017095 @default.
• W1918584766 cites W2041220983 @default.
• W1918584766 cites W2063285149 @default.
• W1918584766 cites W2078251659 @default.
• W1918584766 cites W2086414517 @default.
• W1918584766 cites W2087104615 @default.
• W1918584766 cites W2117115804 @default.
• W1918584766 cites W2120733999 @default.
• W1918584766 cites W2124509162 @default.
• W1918584766 cites W2137523463 @default.
• W1918584766 cites W2138363476 @default.
• W1918584766 cites W2141769755 @default.
• W1918584766 cites W2150652264 @default.
• W1918584766 cites W2151338378 @default.
• W1918584766 cites W2222306685 @default.
• W1918584766 cites W2321119966 @default.
• W1918584766 cites W3114412741 @default.
• W1918584766 cites W2020955707 @default.
• W1918584766 doi "https://doi.org/10.1186/s12876-015-0328-9" @default.
• W1918584766 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4523924" @default.
• W1918584766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26239732" @default.
• W1918584766 hasPublicationYear "2015" @default.
• W1918584766 type Work @default.
• W1918584766 sameAs 1918584766 @default.
• W1918584766 citedByCount "19" @default.
• W1918584766 countsByYear W19185847662016 @default.
• W1918584766 countsByYear W19185847662017 @default.
• W1918584766 countsByYear W19185847662018 @default.
• W1918584766 countsByYear W19185847662019 @default.
• W1918584766 countsByYear W19185847662023 @default.
• W1918584766 crossrefType "journal-article" @default.
• W1918584766 hasAuthorship W1918584766A5009529288 @default.
• W1918584766 hasAuthorship W1918584766A5015644990 @default.
• W1918584766 hasAuthorship W1918584766A5024301901 @default.
• W1918584766 hasAuthorship W1918584766A5025956524 @default.
• W1918584766 hasAuthorship W1918584766A5035616011 @default.
• W1918584766 hasAuthorship W1918584766A5043687105 @default.
• W1918584766 hasAuthorship W1918584766A5044320481 @default.
• W1918584766 hasAuthorship W1918584766A5056815916 @default.
• W1918584766 hasAuthorship W1918584766A5058992298 @default.
• W1918584766 hasAuthorship W1918584766A5063340992 @default.
• W1918584766 hasAuthorship W1918584766A5072719414 @default.
• W1918584766 hasAuthorship W1918584766A5090959657 @default.
• W1918584766 hasBestOaLocation W19185847661 @default.
• W1918584766 hasConcept C126322002 @default.
• W1918584766 hasConcept C203014093 @default.
• W1918584766 hasConcept C2522874641 @default.
• W1918584766 hasConcept C2776235749 @default.
• W1918584766 hasConcept C2776408679 @default.
• W1918584766 hasConcept C2776455275 @default.
• W1918584766 hasConcept C2776461080 @default.
• W1918584766 hasConcept C2776999253 @default.
• W1918584766 hasConcept C2777214474 @default.
• W1918584766 hasConcept C2778390639 @default.
• W1918584766 hasConcept C2780040827 @default.
• W1918584766 hasConcept C41260117 @default.
• W1918584766 hasConcept C71924100 @default.
• W1918584766 hasConcept C72563966 @default.
• W1918584766 hasConcept C90924648 @default.
• W1918584766 hasConceptScore W1918584766C126322002 @default.
• W1918584766 hasConceptScore W1918584766C203014093 @default.
• W1918584766 hasConceptScore W1918584766C2522874641 @default.
• W1918584766 hasConceptScore W1918584766C2776235749 @default.
• W1918584766 hasConceptScore W1918584766C2776408679 @default.
• W1918584766 hasConceptScore W1918584766C2776455275 @default.
• W1918584766 hasConceptScore W1918584766C2776461080 @default.
• W1918584766 hasConceptScore W1918584766C2776999253 @default.
• W1918584766 hasConceptScore W1918584766C2777214474 @default.
• W1918584766 hasConceptScore W1918584766C2778390639 @default.
• W1918584766 hasConceptScore W1918584766C2780040827 @default.
• W1918584766 hasConceptScore W1918584766C41260117 @default.
• W1918584766 hasConceptScore W1918584766C71924100 @default.
• W1918584766 hasConceptScore W1918584766C72563966 @default.
• W1918584766 hasConceptScore W1918584766C90924648 @default.
• W1918584766 hasIssue "1" @default.

• next